The Men's Health Crisis and the Role of Testosterone
It’s time to talk about a silent crisis affecting men’s health: the significant and ongoing decline in testosterone levels.
In a 24-year study, researchers noted a substantial drop in testosterone levels among males in the U.S., and it’s not just due to aging. Men born in more recent years have lower testosterone levels than previous generations, with average levels declining by about 1% per year since the study began in 1987.3
What Does This Mean for You?
Testosterone is more than just a hormone; it’s integral to your vitality. Testosterone deficiency influences everything from muscle mass and bone density to mood and sexual health.
What Can You Do About It?
Be the hero of your life again! Recognize the changes in your body and take action for your health. This decline in testosterone is a public health issue, one that speaks directly to the core of men’s health and well-being.
Symptoms of Low Testosterone
Do These Symptoms Sound Familiar?
- Fatigue or low energy
- Low sex drive
- Trouble sleeping
- Loss of muscle mass
- Decreased bone density
- Weight gain
- Depression
- Anxiety
If so, you may have Low T. Talk to your doctor about your symptoms and ask them to check your testosterone levels.
Low testosterone can affect men at any age, including approximately 35% of men older than 45.4
The Safety of Testosterone Replacement Therapy (TRT)
Insights from the TRAVERSE Study
The TRAVERSE study is the largest randomized clinical trial of testosterone replacement therapy (TRT) to date.5 It was designed to examine the effects of TRT (1.62% testosterone gel) versus placebo on cardiovascular and prostate health, a long-debated topic within the medical community. The study enrolled 5,246 men aged 45 to 80 with documented low testosterone and pre-existing or a high risk of cardiovascular disease.
Cardiovascular Health and TRT6
Study Participants
- Patients with preexisting cardiovascular disease: 2,847
- Patients at elevated cardiovascular risk: 2,357
Findings from the TRAVERSE Study
TRT did not increase the risk of major heart problems compared to a non-treatment placebo.
Prostate Health and TRT7
Study Participants
- Men at greater risk of prostate cancer were excluded, leaving a total of 5,204 participants.
Findings from the TRAVERSE Study
Incidences of high-grade or any prostate cancer were low, and there were no significant differences between testosterone-treated and placebo groups, except for increased prostate-specific antigen concentrations in the testosterone-treated group compared to the placebo-treated group.
These findings from the TRAVERSE study help provide a clearer picture of TRT’s safety. However, your doctor should still monitor your blood pressure while you are being treated with KYZATREX and should check you for prostate cancer or any other prostate problems before you start and while you take KYZATREX.
References:
- Li Y, Liu M, Cui Y, et al. Increased risk of testosterone deficiency is associated with the systemic immune-inflammation index: a population-based cohort study. Front Endocrinol. 2022; 13:975773. doi: 10.3389/fendo.2022.974773
- National Population by Characteristics: 2020-2022. Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States: April 1, 2020 to July 1, 2022 (NC-EST2022- SYAEXN). U.S. Census Bureau.
- Travison TG, Araujo AB, O’Donnell AB, et al. A Population-Level Decline in Serum Testosterone Levels in American Men. J Clin Endocrinol Metab. January 2007, 92(1):196-202.
- Endocrine Society.”Hypogonadism in Men | Endocrine Society.” Endocrine.org, Endocrine Society, 31 January 2024, https://www.endocrine.org/patient-engagement/endocrine-library/hypogonadism. Accessed 2 Feb. 2024.
- Khera M, Rendon DO, et. Al. Lessons learned from the TRAVERSE trial. The Journal of Sexual Medicine. 2024;16(9):746-748.
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023; 389:107-117. DOI: 10.1056/NEJMoa2215025
- Bhasin S, Travison TG, Pencina KM, et al. Prostate safety events during testosterone replacement therapy in men with hypogonadism: a randomized clinical trial. JAMA Netw Open. 2023;6(12):e2348692. doi:10.1001/jamanetworkopen.2023.48692
